

ANNUAL REPORT 2025



wfh.org

Table of contents

Another step towards Treatment for All	1	Making progress: advocate for safe and sustainable treatment and care	10
Our vision and mission	1	World Hemophilia Day 2025: Another great success	12
Letters from the President and the CEO	2	WFH hosts biggest-ever WFH Comprehensive Care Summit.....	14
Making progress against the 2021-2025 Strategic Plan	2	Thank you to our community and corporate partners and to our donors	15
Making progress: identify and diagnose people living with bleeding disorders.....	4	Financial Report 2025.....	20
Making progress: provide adequate care and treatment	6	WFH Board of Directors	24
Making progress: collect, interpret, and disseminate data	8		



ANOTHER STEP TOWARDS TREATMENT FOR ALL

The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world.

At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide the tools needed to identify, support and treat people living with inherited bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals.

OUR VISION AND MISSION

Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world.



.....

As we reflect on 2025, I am proud of the meaningful progress made by the World Federation of Hemophilia and our global community, including landmark improvements to the WHO Essential Medicines List and advocacy at the 78th WHA to expand access to safer and more effective therapies. Working closely with our NMOs, partners, and volunteers, we remain committed to advancing innovation, strengthening advocacy, and moving closer to our shared vision of Treatment for All."

—Cesar Garrido, President, WFH



Letters from the

PRESIDENT AND THE CEO OF THE WFH

Dear friends,

As we reflect on 2025, I am proud to share that this past year marked meaningful progress for the World Federation of Hemophilia and our global community.

One of the most significant milestones we realized together in 2025 was the successful mobilization of the global community to achieve landmark improvements to the World Health Organization's (WHO) Essential Medicines List, expanding access to safer and more effective therapies worldwide. We also represented the community at the 78th World Health Assembly (WHA), advocating for stronger international commitments to improving care and treatment. Furthermore, the WFH issued a call to action for continued innovation and access in hemophilia care on the part of our pharmaceutical partners.

The Comprehensive Care Summit in Dubai exceeded expectations and sparked important conversations about future collaboration and innovation. The success of this event is already informing how we design future meetings and engage our global community; it's also helping us identify potential revenue opportunities to support the WFH.


Throughout the year, I continued working closely with our national member organizations (NMOs). Listening to our NMOs remains essential to understanding local realities and ensuring our strategies reflect on-the-ground needs. Through visits and ongoing dialogue, we reinforced partnerships and strengthened advocacy efforts.

We realized many other significant accomplishments in 2025, including the publication of the *Third Edition of Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual*, new educational resources on gene editing and genetic technologies, and the release of the *WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy, 2025*. We also expanded our Shared Decision Making tool, launched the WBDR Data Dashboard, and held a number of successful events, such as the 14th WFH Global Forum, the fourth WFH Global Summit on Women and Girls with Bleeding Disorders, and the fourth edition of the WFH Global Policy and Access Summit (GPAS).

Looking ahead to 2026, our priorities remain clear: improving diagnosis, strengthening access to care and treatment, enhancing data, and continuing to advocate for safe and sustainable care worldwide.

I extend my sincere thanks to our staff, volunteers, NMOs, and partners. Together, we will continue working toward our shared vision of Treatment for All.

Sincerely,



Cesar Garrido
President,
World Federation
of Hemophilia



Making progress against the 2021–2025 STRATEGIC PLAN

The WFH actively monitors KPIs related to our four areas of capacity building.

Note: KPIs reflect 2025 results, except Annual Global Survey indicators, which are only available for 2024 at publication.



IDENTIFY
and diagnose people living with bleeding disorders



PROVIDE
adequate care and treatment



COLLECT,
interpret, and disseminate data



ADVOCATE
for safe and sustainable treatment and care



Dear friends,

As we close out 2025, I am proud to look back on a year defined by strong results, collaboration, and clear progress toward our shared goals—especially those in our strategic objectives.

In 2021, the WFH launched the 2021–2025 Strategic Plan to advance its vision of Treatment for All—for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live.

This Strategic Plan was grounded in a clear theory of change: by collaborating with NMOs, healthcare providers, and governments, the WFH would help accelerate progress across health systems and improve outcomes for people with inherited bleeding disorders. The Strategic Plan was built around seven priorities: training and education; standards of excellence for NMOs; strengthened global advocacy; improved identification; aligned programs and tools; a reimagined WFH culture; and sustainable financial health.

To strengthen accountability and demonstrate progress around the priorities of the Strategic Plan, the WFH monitored several key performance indicators (below). The results of our efforts are shown here.

- **Identify and diagnose people living with bleeding disorders.**

The WFH set a five-year objective of a 25% increase in the number of people with hemophilia diagnosed and reported through the WFH Annual Global Survey (AGS), and a 25% increase in people living with von Willebrand disease (VWD). After four years, hemophilia diagnosis is on track, while VWD diagnosis is already above target.

- **Provide adequate care and treatment.**

The WFH set a five-year goal to reach a cumulative 30,000 people with hemophilia receiving humanitarian aid. This target was exceeded, with 34,747 people treated through the WFH Humanitarian Aid Program. We also achieved our objective of reaching 4,000 children on prophylaxis through humanitarian aid over five years—supporting a shift toward preventive and more predictable models of care.

- **Collect, interpret, and disseminate data.**

The World Bleeding Disorders Registry (WBDR) surpassed the goal of 10,000 registered patients—reaching nearly 19,000—further reinforcing evidence generation and long-term monitoring. The WFH set a goal to expand participation in the AGS by 20 new or returning NMOs over five years. This target was achieved, strengthening the global representativeness and value of WFH data.

- **Advocate for safe and sustainable treatment and care.**

The WFH also supported sustainable systems change—24 countries adapted treatment guidelines, and 64 instances of increased government support for bleeding disorders care have been recorded across 37 countries—exceeding our initial targets and reflecting a sustained and repeated commitment across several countries.

As we conclude the 2021–2025 Strategic Plan, the WFH is well-positioned to build on the progress we achieved together. We remain committed to accelerating impact where needs are greatest—supporting NMOs and healthcare teams, advancing evidence and data, strengthening advocacy, and working with partners to expand sustainable access to treatment and care.

I extend my sincere thanks to our staff, volunteers, NMOs, and partners for the help they provided to us over the last five years. Together, we were able to meet our goals in the Strategic Plan, and together we will continue working toward our shared vision of Treatment for All.

With gratitude and best wishes,



Alain Baumann
Chief Executive Officer (CEO),
World Federation
of Hemophilia



Making progress:

IDENTIFY AND DIAGNOSE PEOPLE LIVING WITH BLEEDING DISORDERS

Results for 2025 - **Highlights**

Sustained support for women and girls with bleeding disorders (WGBDs) by dedicating the 2025 World Hemophilia Day theme to women and girls, organizing the biennial Global Summit for Women and Girls with Bleeding Disorders and initiating pilot projects in Mexico and Paraguay to established specialized diagnosis care services for WGBDs.

Supported laboratory best practices through the publishing of the *Third Edition of Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual*




WFH impact

COMMUNITY STORY



“Hello, my name is Yannick, I’m 61 and now I know that I’m living with mild hemophilia A. I will speak about my journey for recognition. Years of wondering; I lived for years with symptoms, bruises...”

Diagnosis of people with hemophilia (PWH)




**5-YEAR
GOAL:
25%
INCREASE**

Globally, two-thirds of people with hemophilia remain undiagnosed. The 5-year goal (2020 to 2025) of the WFH is to increase the number of people diagnosed with hemophilia by 60,000 (25%).

Data Source: WFH Annual Global Survey (only 2024 data available at the time of publication).

Diagnosis of people with von Willebrand disease (VWD)



**5-YEAR
GOAL:
25%
INCREASE**

VWD is the most common bleeding disorder with an estimated 1 in 1,000 individuals impacted—but it remains vastly underdiagnosed. The 5-year goal (2020 to 2025) of the WFH is to increase the number of people diagnosed with VWD by 110,000 (25%).

Data Source: WFH Annual Global Survey (only 2024 data available at the time of publication).

Then 10 years ago, some hematologists started to say that women and girls have symptoms which look like those of PWH. For me the end of years of wondering—I was nearly 60.

Now I can say I am living with my hemophilia A and it was treated and cared by HCPs. I hope that all women and girls with bleeding disorders could now be diagnosed, cared and treated without years of wondering.”

—Yannick Collé, France
Person with hemophilia A



Click here to read the full story or scan the QR code

Making progress:

PROVIDE ADEQUATE CARE AND TREATMENT

Results for 2025 - Highlights

Explored advances and access to care through the 14th WFH Global Forum


Promoted research into the potential of myofascial therapy (MFT) through the WFH Research Support Program (RSP)

Enriched gene therapy knowledge through the release of *Genetic Technologies for Hemophilia and the WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy, 2025*

Extended WFH Humanitarian Aid Program partnerships with Sanofi, Sobi and Takeda

Ensured the WFH Shared Decision Making Tool was updated as new treatments for hemophilia became available

Celebrated three decades of impact for the WFH Twinning Program



WFH impact CASE STUDY

New chapter on AAV gene therapy added to treatment guidelines

The WFH has published treatment guidelines for hemophilia since 2005, with updates in 2013 and 2020 (3rd edition). These guidelines are crucial for standardizing clinical practice, ensuring patient safety, and supporting informed and shared decision-making. In 2025, a new chapter on adeno-associated virus (AAV) gene therapy was added to the guidelines.


Cumulative number of PWH receiving humanitarian aid



**5-YEAR
GOAL:
30,000
PWH**

The overwhelming majority of people living with inherited bleeding disorders around the world still do not have access to treatment and care. The 5-year goal (2020 to 2025) of the WFH is to increase the number of new PWH receiving WFH Humanitarian Aid Program donations to 30,000 people (35%).

Prophylaxis use among children benefiting from humanitarian aid



**5-YEAR
GOAL:
4,000
CHILDREN**

The WFH Hemophilia Treatment Guidelines have established that prophylaxis is the global standard of care for people with severe hemophilia. The 5-year goal (2020 to 2025) is to reach 4,000 children with hemophilia receiving prophylaxis through the WFH Humanitarian Aid Program.

Developed with input from clinical experts, people with hemophilia, and caregivers, the *WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy, 2025* provide evidence-based recommendations for the safe and effective implementation of AAV gene therapy. The key topics covered in the guidelines include site preparedness; shared decision-making (SDM); eligibility, suitability, and screening; infusion day guidance; and post-infusion care recommendations.



Click here to read the full story or scan the QR code

Making progress:

COLLECT, INTERPRET, AND DISSEMINATE DATA

Results for 2025 - Highlights

Record number of respondent countries contributed data to the *Annual Global Survey 2024*, offering comprehensive global data to researchers and advocates

Enabled more efficient data exploration for researchers through the WBDR Data Dashboard



WFH impact CASE STUDY

WFH launched the WBDR Data Dashboard

In 2025, the WFH launched a WBDR Data Dashboard, which transforms data into useful metrics and insights that can be leveraged for a wide range of purposes, such as advocacy and research. The tool provides users with real-time insights into key metrics such as patient demographics and clinical outcomes. The tool allows HTC, healthcare professionals, and researchers to analyze trends and disparities in diagnosis, treatment and care, with the goal of informing patient outcomes, resource allocation and health policies.


New patients registered in the WFH World Bleeding Disorders Registry (WBDR)



5-YEAR GOAL:
10,000 PWH OR VWD

The WBDR provides a web-based data entry platform to a large network of participating HTC's to collect and manage their data. From 2021 to 2025, the WFH aims to register 10,000 new patients with hemophilia or VWD in the WBDR.

Expanded reach of the Annual Global Survey (AGS)



5-YEAR GOAL:
20 NEW OR RETURNING NMOs

Many countries lack the data they need to fully support community and advocacy efforts. The 5-year goal of the WFH (2021 to 2025) is for 20 new or returning NMOs to report country data to the AGS.

Data can be filtered by several fields, such as hemophilia type, severity, age group, region and country. Visualizations can then be presented as a demographic summary, a demographic visualization, a map, a clinical summary, or a diagnosis, outcomes, or treatment visualization.



Click here to read the full story or scan the QR code

Making progress:

ADVOCATE FOR SAFE AND SUSTAINABLE TREATMENT AND CARE

Results for 2025 - Highlights

Provided open forum for discussion and exchange on effective strategies to increase equitable access to care and treatment through the WFH Global Policy and Access Summit (GPAS)

Mobilized the global community to achieve milestone revisions to the WHO Essential Medicines List (EML)

Improved the organizational development skills of future community leaders through the WFH 2025 Global Youth Leadership Training

Represented People with bleeding disorders (PWBDs) to initiate a global call to action for bleeding disorders at the 78th World Health Assembly



WFH impact CASE STUDIES

WFH mobilizes global community to achieve landmark improvements to WHO EML

A concerted effort by the WFH and its partners has led to the World Health Organization (WHO) updating its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the management of hemophilia and VWD. The revisions introduced in the recently published 24th EML and 10th EMLc will help to increase equitable access to safer and more effective therapies for PWBDs worldwide.

The process included the WFH undertaking a two-year-long ongoing direct dialogue with the WHO headquarters and consulting with the EML Secretariat closely throughout the application process. The WFH was also an active participant at the meeting of the WHO 25th Expert Committee on the Selection and Use of Essential Medicines, and made a statement in favour of updating the guidelines during the public session on May 5, 2025.

This milestone for our community was realized thanks to a joint effort led by the WFH, underscoring the wide-reaching commitment across institutions, experts, and organizations to update the EML.



Click here to read the full story or scan the QR code

Using the WFH Treatment Guidelines



**5-YEAR
GOAL:
20 NEW
COUNTRIES**

WFH Treatment Guidelines serve as a powerful tool to guide best practices for bleeding disorders treatment and care, and support advocacy efforts. The 5-year goal (2021 to 2025) of the WFH is for 20 new countries to produce new or updated national guidelines or policies based on the WFH Treatment Guidelines.

Increasing government support



**5-YEAR
GOAL:
30 NEW
COUNTRIES**

One of the main goals of the WFH is to build the capacity of NMOs and HCPs to advocate for safe and sustainable treatment and care. The 5-year goal (2021 to 2025) of the WFH is to have 30 countries increase government support for bleeding disorder treatment and care.

WFH Global NMO training six-month impact

The 2025 Global NMO Training (GNMOT) focused on key areas such as stakeholder collaboration, good governance, project proposal development, budgeting and financial reporting, and monitoring and evaluation. The training was attended by 108 participants from 91 countries. Six months after the training, participants were surveyed on how the training impacted their work and the value of the tools that were made available for them. When asked for the impact of the training on their NMO, 61% reported increased advocacy work, 67% reported better project planning, and 55% reported enhanced strategic planning. Overall, the feedback was highly positive, with 95% of participants considering the training content relevant to their work and 79% reporting increased knowledge post-training.



 [Click here to read the full story or scan the QR code](#)

WORLD HEMOPHILIA DAY 2025: ANOTHER GREAT SUCCESS



World
Hemophilia
Day April 17

Recognizing all bleeding disorders

The theme of World Hemophilia Day last year was **“Access for all: Women and girls bleed too”**, and the community enthusiastically celebrated this cause on April 17, 2025. Celebrations took place across the globe, with buildings and monuments lit up in red. Online, excitement surged as the global bleeding disorders community came together once again to mark this important day. A record 175+ monuments took part in the “Light it up Red” campaign, and hundreds of gatherings took place in different cities around the world.

780,000

impressions
on social media

48,000


views on the World
Hemophilia Day website

252,000

video views

175+

buildings and monuments
participated in the Light it Up
Red campaign



#WHD2025

#WeBleedToo

COMMUNITY STORIES



“My name is Muhiba Amir. I’m 18 years old. I’m a person with VWD. I am a pre-med student at the Punjab group of colleges.

I was diagnosed with VWD when I was six months old. Due to the support of my parents and family, I managed my studies along with VWD. My teachers were also very cooperative.

Now... I enjoy a better lifestyle with VWD because I can get information from the hemophilia patients welfare society in Lahore.”

—Muhiba Amir, Pakistan
Person with von Willebrand disease (VWD)



[Click here to read the full story or scan the QR code](#)



“My Name is Mohamad Abdulkader Lababidi. I was born and raised in Aleppo, Syria—a city once celebrated for its ancient citadels and bustling markets, now scarred by war.

My life has been a relentless dance between two forces: ‘hemophilia’, a genetic disorder I inherited, and the chaos of a conflict that turned streets into battlegrounds.

These twin struggles have shaped who I am, but they have not defined my limits.”

—Mohamad Abdulkader Lababidi, Syrian Arab Republic
Person with hemophilia A



[Click here to read the full story or scan the QR code](#)

WFH 2025

WFH HOSTS BIGGEST-EVER WFH COMPREHENSIVE CARE SUMMIT

The WFH 2025 Comprehensive Care Summit—which encompassed the previous biennial International WFH Musculoskeletal (MSK) Congress—was held in Dubai, U.A.E. in April 2025. The event was the biggest ever CCS meeting held by the federation, and featured specialized tracks for MSK, medical professionals, and people with bleeding disorders, bringing together experts, patients, and advocates from around the world. Participants had the chance to engage in dynamic discussions with their peers and today's thought leaders on cutting-edge research, innovative treatments, and the pressing challenges in our community.

838

in-person attendees

91%

participant satisfaction rate

3

awards presented

119

speakers

232

abstracts

49

sessions

“The WFH 2025 Comprehensive Care Summit: New Developments in Bleeding Disorders & MSK highlighted the importance of different aspects of care in the comprehensive care framework, and the importance of exploring innovative approaches to care.”

—Cesar Garrido, WFH President



Photo: The WFH 2025 Comprehensive Care Summit in Dubai.

SAVE THE DATE!

WFH 2026
WORLD CONGRESS

APRIL 19-22,
KUALA LUMPUR,
MALAYSIA



WFH 2026
WORLD CONGRESS



WFH COMPREHENSIVE
CARE SUMMIT

#WFHCCS

I'M ATTENDING THE
**WFH 2025
Comprehensive
Care Summit**

3-25 2025 | Dubai, U.A.E.



HEMNET

WFH
WORLD FEDERATION OF HEMOPHILIA
ASSOCIATIONS





Dr. S. Hansingo
Gynaecologist

FINANCIAL REPORT 2025



(All amounts are in thousands of CAD dollars,
unless stated otherwise)

In 2025, the World Federation of Hemophilia’s staff and volunteers continued to advance impactful, high-quality initiatives that supported and strengthened the global inherited bleeding disorders community.

The year ended with a net surplus of \$1,679 compared to a budgeted net deficit of \$945. This represents a significant improvement of \$2,624 over budget. A key contributor to the favourable outcome was the outstanding performance of our investments as financial markets remained strong throughout the year. The strong U.S.A. currency (which averaged \$1.40 CAD for the year) further contributed to the positive result.

Continued revenue stability

Our corporate sponsors continued their invaluable support with 2025 contributions of \$6,532, an increase of \$188 (3%) over 2024. This increased funding was for the most part applied to the Humanitarian Aid General Program, the Women and Girls Bleeding Disorders programs, and the biennial WFH Global Forum (GF) which took place in 2025. Steady funding was also received for our global development programs including the WFH Twinning Program and the WFH Path to Access to Care and Treatment (PACT) Program.


In 2025, the WFH Humanitarian Aid Program spent \$5,493 (\$4,756 in 2024) from funding received from our key partners. As per Canadian accounting rules, revenues received for restricted purposes can only be recognized in the year in which related expenses are incurred. With these funds, along with donated products, the WFH was able to treat 18,387 people with inherited bleeding disorders in 75 emerging countries.

For WFH Research Programs, which is also a restricted program, \$1,598 was recognized (\$1,690 in 2024). These funds were put towards the WFH Gene Therapy Registry (GTR) to expand our data collection efforts for people with hemophilia A and B who receive this therapy. The funds were also used to ensure the continued success of the WFH World Bleeding Disorder Registry (WBDR)—which now includes more than 19,000 people with hemophilia and von Willebrand disease (VWD) enrolled from 135 hemophilia treatment centres (HTCs) in 49 countries globally.


Fundraising revenues were at \$1,032 (\$1,186 in 2024). This was due to the generous donations from our community partners to fund various programs, including the Global Youth Leadership Training, the WFH Cornerstone Initiative, and the Humanitarian Aid General Program.

Investment income reached \$1.2 million (\$1.3 million in 2024), with long- and short-term investments contributing almost equally to this result. On the long-term side (\$571), Canadian and emerging markets led global returns in 2025 despite tariff-related turbulence earlier in the year. Fixed income investments also generated solid returns with approximately one-third coming from hedging strategies. Short-term investments brought in \$610, consisting of interest income from numerous GICs (Guaranteed Investment Certificates) which are conservative investments with guaranteed capital and varying maturity dates and rates. Total WFH revenue, before Congresses and Product Donations, reached \$16,485—\$695 (4%) above 2024.

As the WFH delivers the biennial WFH World Congress as well as other WFH meetings over a two-year period, it is typical for us to combine and review our results over a two-year cycle. As shown in Figure 1, excluding product donations, 32% of revenues over the two-year cycle are from sponsorships from WFH corporate partners; 33% are from restricted programs (Humanitarian Aid and the Research Program); 20% are from revenues from the WFH 2024 World Congress and the WFH 2025 Comprehensive Care Summit (CCS); and the remaining 15% are generated from investments, community partners, and other revenues including national member organization (NMO) assessments.



HUMANITARIAN AID PROGRAM & MEDICAL TRAINING	34.4%	ADMINISTRATION	5.4%
CONGRESS AND COMPREHENSIVE CARE SUMMIT	22.4%	FUNDRAISING AND CORPORATE RELATIONS	3.7%
GLOBAL DEVELOPMENT PROGRAMS	15.4%	GOVERNANCE AND COMMUNICATIONS	3.5%
DATA AND RESEARCH	15.3%	FLUCTUATION OF FOREIGN EXCHANGE	-0.1%



Expenditures aligning with strategic objectives

In aggregate, the global development programs, data and research programs, and the humanitarian aid and medical training programs continued to represent the major proportion of expenditures at 65% of total costs incurred over the past two years, as seen in Figure 2. The WFH 2025 Comprehensive Care Summit and the WFH 2024 World Congress represented an investment of 22% of WFH expenditures, while fundraising and corporate relations costs represented 4% of the total. Expenses attributed to running the WFH organization included administration at 5%, and governance and communications at 4%.

Humanitarian aid

The WFH distributes life-saving and life-sustaining treatment product donations from many of our corporate sponsors to WFH NMOs and HTCs around the world. In 2025, the WFH distributed 298 million IUs of factor and 2.2 million mg of non-factor replacement therapy, helping over 18,000 people with inherited bleeding disorders get the treatment they needed.

These donations are included in the audited financial statements of WFH USA. The total value of all products shipped from WFH USA was over \$1.1 billion USD.

WFH 2025 Comprehensive Care Summit

The 2025 Comprehensive Care Summit in Dubai was a success from an education and global community networking standpoint with 838 delegates attending from 90 countries. It also did well financially, as it brought in a surplus of \$194.

Year-over-year comparison

The 2025 and 2024 statement of revenues and expenses, illustrated in Figure 3, reflects the fluctuations within a typical two-year cycle where the WFH World Congress is held in even years, where the WFH Global Forum and CCS are held in odd years, and where the receipt of product donations varies in terms of frequency and amount.

On the revenue side, before Congresses and Product Donations, there was a growth of \$695, as already mentioned above. This was largely due to the increases in contributions from our corporate partners to the WFH Humanitarian Aid Program (\$737); the biennial WFH Global Forum, that was held in 2025 (\$258); and the Women and Girls Bleeding Disorders programs (\$148). This was partially offset by decreased revenues for the WBDR (\$162), decreased fundraising revenues from community partners (\$154) and slightly less investment income (\$123) versus 2024 which was a record year for investments.

The overall spend of \$15,040 before Congresses and Product Donations (\$14,211 in 2024) reflects the continued efforts of the WFH to support the needs of the global bleeding disorders community. This was highlighted by the major increase of \$1,139 for the WFH Humanitarian Aid Program that delivered treatment to those who needed it most; and \$152 for the Global Youth Leadership Training. This was offset by a decrease in Administration costs mostly due to reduced rent (\$347) as a result of having moved our office to much smaller premises in 2025. In addition, there were reduced Global Development expenses of \$168 as the WFH Global NMO Training took place in 2024 as well as a \$162 decrease for the WBDR due to reduced funding for this program.

Looking ahead

Our financial base is currently strong, with net assets of \$17.5 million. However, congresses which are critical in funding our programs and activities over a two-year period can no longer be relied upon to bring in the surpluses that they have in prior years. This was evidenced by the weak results of both our 2022 and 2024 World Congresses which had fewer participants and higher costs than expected. Corporate sponsorship has also decreased, due to both a reduction in the number of partners as well as lower contributions than in the past. Furthermore, the current state of the global economy due to geopolitical shocks has already started to have a negative impact on the US dollar and, in addition, may result in decreased investment revenues.

The WFH will need to rely on the continued support and flexibility of our corporate and community partners to be able to carry out our important work as we continue to broaden our revenue generation efforts through various other fundraising sources.

Our careful management of resources allowed us to build a robust base of reserves that we are using to mitigate the impact of financial uncertainties. Our senior management team has also been proactive in mitigating some of these downward trends by continuing to execute expense control measures.

As ever, we will continue to focus our efforts and resources for the benefit of our community so we can get closer to our vision of Treatment for All.

FIGURE 3

Revenues and expenses

(Expressed in Canadian dollars)

	2025	2024
REVENUES		
Corporate Partnerships	6,531,933	6,343,975
Humanitarian Aid Program	5,492,598	4,755,988
Research Program	1,597,707	1,689,968
Community Partnerships	1,031,705	1,186,150
Investments	1,180,421	1,303,305
Other Revenue	650,873	510,999
Total Revenues before Congresses and Product Donations	16,485,237	15,790,385
Congress and Comprehensive Care Summit	1,411,509	6,821,784
Product Donations		7,249,785
TOTAL REVENUES	17,896,746	29,861,954
EXPENSES		
Humanitarian Aid Program & Medical Training	6,926,652	6,019,167
Global Development Programs	2,988,732	2,822,420
Data & Research	2,824,567	2,940,970
Fundraising & Corporate Relations	703,724	693,980
Governance and Communications	678,945	645,737
Administration	863,882	1,180,780
Fluctuation of Foreign Exchange	53,980	(92,109)
Total Expenses before Congress and Product Donations	15,040,482	14,210,945
Congress and Comprehensive Care Summit	1,177,447	7,263,533
Product Donations		7,249,785
TOTAL EXPENSES	16,217,929	28,724,263
EXCESS (DEFICIENCY)	1,678,817	1,137,691



THANK YOU

to our community and corporate
partners and to our donors



OUR CORPORATE PARTNERS

The WFH gratefully acknowledges the generous support of our dedicated partners in 2025. Our Corporate Partners all play a significant role in helping us improve and sustain care for people with bleeding disorders around the world.

Global Partnership Recognition

Global partnership recognition is based on our Corporate Partners' overall annual support and recognizes multiyear commitments and alignment with our strategic priorities. We are pleased to acknowledge our 2025 Visionary, Leadership and Collaborating Partners.

Visionary Partners	Leadership Partners	Grifols
CSL Behring	Sobi	Kedrion
F. Hoffmann-La Roche	Collaborating Partners	LFB
Pfizer	Bayer	Novo Nordisk
Sanofi	BioMarin Pharmaceutical Inc.	Octapharma
		Regeneron
		Takeda

WFH programs and activity support in 2025

Corporate Partner Program

Visionary Partners	Contributing Partners
CSL Behring	BioMarin Pharmaceutical Inc.
F. Hoffmann-La Roche	Grifols
Pfizer	Kedrion
Sanofi	LFB
Collaborating Partners	Regeneron
Bayer	
Novo Nordisk	
Octapharma	
Sobi	
Takeda	

WFH Humanitarian Aid Program

Founding Visionary
Sanofi
Sobi

Visionary Contributors
Bayer
CSL Behring
F. Hoffmann-La Roche

Leadership Contributor
Grifols

Contributor
Takeda

WFH Path to Access to Care and Treatment (PACT) Program

Visionary Partners
F. Hoffmann-La Roche
Sanofi

Leadership Partners
CSL Behring
Pfizer

WFH World Bleeding Disorders Registry (WBDR)

Visionary Partner
Sobi

Collaborating Partners
Grifols
Pfizer
Sanofi

WFH Gene Therapy Registry (GTR)

Visionary Partners
BioMarin Pharmaceutical Inc.
CSL Behring
Pfizer

Sponsored programs

WFH Gene Editing Education
Regeneron

WFH Global Forum
BioMarin Pharmaceutical Inc.
CSL Behring
Pfizer
Sanofi
Sobi

WFH International External Quality Assessment Scheme Program (IEQAS)
Novo Nordisk Haemophilia & Haemoglobinopathies Foundation

WFH Shared Decision Making Tool
F. Hoffmann-La Roche
Novo Nordisk
Pfizer
Sanofi
Sobi

WFH Twinning Program
Pfizer

Women and Girls with Bleeding Disorders Initiative
F. Hoffmann-La Roche
LFB
Sanofi

Ultrasound and Synovectomy Workshop
CSL Behring
F. Hoffmann-La Roche
Sanofi
Sobi

WFH 2025 Comprehensive Care Summit

Platinum Sponsors
Sanofi
Sobi
Roche

Gold Sponsors
Pfizer
Regeneron
Takeda

Other product donations

Bayer
CSL Behring
HEMA Biologics, LLC
Octapharma
Pfizer
Sobi
Takeda

\$500,000+

Hemophilia of Georgia, Inc.

\$250,000 to \$499,000

Glenn Pierce and Marianna L. Battazza

\$100,000 to \$249,999

The Hemophilia Alliance

\$50,000 to \$99,999

Canada's Drug Agency/L'Agence des
medicaments du Canada

John Cox

Indiana Hemophilia and Thrombosis Center

National Bleeding Disorders Foundation

Sanofi

George Scangos

Jeannie and Leonard A. Valentino

\$25,000 to \$49,999

Beatrice Pierce

Mark Skinner and James Matheson

\$10,000 to \$24,999

Assad Haffar

HemoHelper

Oasis Foundation

\$5,000 to \$9,999

Barbara Goldman

Infucare RX Inc

Phillip Kucab

Alvin Luk

Sally K. McAlister

Matthew Ottmer and Megan McLean

Metagenomi

John Murphy

Société canadienne de l'hémophilie

Two anonymous donations

\$1,000 to \$4,999

Kelly C. and Penny Atkinson

Paula Bell and Rob Christie

Bleeding Disorders Foundation
of North Carolina

Davis Carman

Patsy Carman

Donna Coffin

Jennifer Dumont

Judy Faitek

Patrick Fogarty

Cesar Garrido

Antonia Luque de Garrido

Gilead

Paul F. Haas

Hemophilia Association

of the Capital Area

Christine Herr

Michael Higgins

Kim Isenberg

Haiyan Jiang

Mark Kay

Barbara Konkle and Peter Kollros

Gallia G. Levy

Stan Marks

Sarah Noonberg

Pacific Northwest Bleeding Disorders

Patricia A. Pascucci

Kimberly Phelan

Meredith Pierce

Nick Pierce

Rana Saifi

Rocky Mountain Hemophilia & Bleeding

Disorders Association

Susan Resnik

Dawn S. Rotellini

Paul Solari

Tides foundation

Weidong Xiao

Xin Zhang

Two anonymous donations

\$500 to \$999

Syed Ali

Alain Baumann

Jeffrey Blake

Jennifer Brennan

Nathan Connell

Joanna A. Davis

Daniel Doran

Santiago Estrada diaz

Dietje E. Fransen van de Putte

InfoMagnetics Technologies Corp.

Kate Khair

Anastasia A. Khasiani

Shuanglian Li

Wendy Quinn

Gina Schnabel

Sean Singh

Southwestern Ohio Hemophilia

Foundation

Marlene Spencer

Eric Stolte

Marion Stolte (in memoriam)

Andreina Tovar

Samantha Truex

Virginia Hemophilia Foundation

Haoling Weng

Western Pennsylvania Bleeding

Disorders Foundation (WPBDF)

Emiy Yokoyama

\$250 to \$499

Accenture

Mohannad Al Zubaidi

Alan Brownstein

Antonio J. Almeida

Gayane Avagyan

Randall G. Curtis

Amy Dunn

Michael Dunn

Elena Galstian

Cedric Hermans

Peter Hultgren

IQM Consulting

Paul Karwatsky

Carol K. Kasper (in memoriam)

Hasmik Manukyan

Danielle Nance

Yasuharu Nishida

David Page

Ulrike Reiss

Patrick and Clare Robert

Pedro Rodriguez Sanchez

Shawn Roman

Maria M. Salas-Pilla

Jill Sallade-Packard

Cees Th.P. Smit Sibinga

Eliza VanZweden

Howard Winet

\$150 to \$249

Per Arne Berg

Binghamton Univeristy

Foundation

Hemophilia Foundation – Pakistan
(HFP)

Hemophilia Philippines (HAPLOS
Community) Foundation

Leslie Klein

Yu Koga

Martin Lampacher

Mayss Naccache

Salem State University

Richard B. Sommers

Terrie Sommers

Patricia Stewart

Camilla Wensing

Wing Yen Wong

Dan Zortman

Tributes

In Honour of Dr. Assad Haffar

In Honour of Glenn Pierce on

his 70th birthday

In Memory of Carol Kasper Winet

In Memory of Donald Goldman

In Memory of Dr. Michael Tidwell

WFH BOARD OF DIRECTORS

We rely on the WFH Board of Directors, WFH staff, and volunteers to support our shared vision of Treatment for All.



Cesar Garrido
President
Venezuela



Barry Flynn
Vice President, Finance
United Kingdom



Emna Gouider
Vice President, NMO
Tunisia



Glenn Pierce
Vice President, Medical
U.S.A.



Alok Srivastava
Medical Member
India



Barbara Konkle
Medical Member
U.S.A.



Cedric Hermans
Medical Member
Belgium



**Daniel-Anibal
García Diego**
Lay Member
Spain



Dawn Rotellini
Lay Member
U.S.A.



Ekawat Suwantaraj
Lay Member
Thailand



Marko Marinic
Lay Member
Croatia



Mathieu Jackson
Lay Member
Canada



Miguel Escobar
Medical Member
U.S.A.



Tatiana Bathfield
Lay Member
Mauritius



Alain Baumann
CEO
Canada

WFH Staff



2025 WFH HIGHLIGHTS

34,700+ PEOPLE

with a bleeding disorder treated
since 1996

135 TREATMENT CENTRES

benefitted from the WBDR

130+ COUNTRIES REACHED

through global programs and events

17,000 USERS

of the WFH Shared Decision Making Tool

WORLD FEDERATION OF HEMOPHILIA

1184, rue Sainte-Catherine Ouest
Bureau 500, Montréal (Québec) H3B 1K1
Canada
T +1 514.875.7944
wfh@wfh.org
wfh.org



Charitable solicitations for the common purposes of WFH and WFH USA within the U.S.A. are conducted through WFH USA, a 501(c)3 affiliated entity.

Printed in Canada – Design: lanla.com

Cover photo: WFH Humanitarian Aid visit in Kyrgyzstan